Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus

References

• aoa.gov [homepage on the Internet]Projected future growth of the older population Administration on Aging (Department of Health and Human Services)2010 [updated June 23, 2010; cited October 4, 2012] Available from: http://www.aoa.gov/AoARoot/Aging_Statistics/future_growth/future_growth.aspx#ageAccessed February 24, 2013
   Google Scholar
• Centers for Disease Control and PreventionNational Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011AtlantaUS Centers for Disease Control and Prevention (Department of Health and Human Services)2011 Available from: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_pdfAccessed December 12, 2012
   Google Scholar
• BrownAFMangioneCMSalibaDSarkisianCACalifornia Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with DiabetesGuidelines for improving the care of the older person with diabetes mellitusJ Am Geriatr Soc200351Suppl Guidelines 5S265S28012694461
   PubMed Web of Science ®Google Scholar
• SinclairAJConroySPBayerAJImpact of diabetes on physical function in older peopleDiabetes Care200831223323518024850
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBAmerican Diabetes Association (ADA)European Association for the Study of Diabetes (EASD)Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetes Care20123561364137922517736
   PubMed Web of Science ®Google Scholar
• SchwartzAVVittinghoffESellmeyerDEHealth, Aging, and Body Composition StudyDiabetes-related complications, glycemic control, and falls in older adultsDiabetes Care200831339139618056893
   PubMed Web of Science ®Google Scholar
• MaraldiCVolpatoSPenninxBWDiabetes mellitus, glycemic control, and incident depressive symptoms among 70- to 79-year-old persons: the health, aging, and body composition studyArch Intern Med2007167111137114417563021
   PubMedGoogle Scholar
• MunshiMGrandeLHayesMCognitive dysfunction is associated with poor diabetes control in older adultsDiabetes Care20062981794179916873782
   PubMed Web of Science ®Google Scholar
• NeumillerJJWoodLCampbellRKDipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitusPharmacotherapy201030546348420411998
   PubMed Web of Science ®Google Scholar
• HandelsmanYMechanickJIBlondeLAACE Task Force for Developing Diabetes Comprehensive Care PlanAmerican Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care planEndocr Pract201117Suppl 2S1S53
   PubMed Web of Science ®Google Scholar
• NathanDMBuseJBDavidsonMBAmerican Diabetes AssociationEuropean Association for Study of DiabetesMedical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care200932119320318945920
   PubMed Web of Science ®Google Scholar
• PratleyREMcCallTFleckPRWilsonCAMekkiQAlogliptin use in elderly people: a pooled analysis from phase 2 and 3 studiesJ Am Geriatr Soc200957112011201919793357
   PubMed Web of Science ®Google Scholar
• PratleyRERosenstockJPi-SunyerFXManagement of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapyDiabetes Care200730123017302217878242
   PubMed Web of Science ®Google Scholar
• HalimiSRaccahDSchweizerADejagerSRole of vildagliptin in managing type 2 diabetes mellitus in the elderlyCurr Med Res Opin20102671647165620441397
   PubMed Web of Science ®Google Scholar
• SchweizerADejagerSFoleyJEShaoQKothnyWClinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥ 75 years: a pooled analysis from a database of clinical trialsDiabetes Obes Metab2011131556421114604
   PubMed Web of Science ®Google Scholar
• BarzilaiNGuoHMahoneyEMEfficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trialCurr Med Res Opin20112751049105821428727
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationNDA Approval [Onglyza New Drug Approval]Silver SpringUS Food and Drug Administration2009 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/022350s000ltr.pdfAccessed October 19, 2011
   Google Scholar
• RosenstockJAguilar-SalinasCKleinENepalSListJChenRCV181-011 Study InvestigatorsEffect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetesCurr Med Res Opin200925102401241119650754
   PubMed Web of Science ®Google Scholar
• HollanderPLiJAllenEChenRCV181-013 InvestigatorsSaxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione aloneJ Clin Endocrinol Metab200994124810481919864452
   PubMed Web of Science ®Google Scholar
• DeFronzoRAHissaMNGarberAJSaxagliptin 014 Study GroupThe efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin aloneDiabetes Care20093291649165519478198
   PubMed Web of Science ®Google Scholar
• ChacraARTanGHApanovitchARavichandranSListJChenRCV181-040 InvestigatorsSaxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trialInt J Clin Pract20096391395140619614786
   PubMed Web of Science ®Google Scholar
• JadzinskyMPfütznerAPaz-PachecoEXuZAllenEChenRCV181-039 InvestigatorsSaxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trialDiabetes Obes Metab200911661162219515181
   PubMed Web of Science ®Google Scholar
• KulasaKEdelmanSSaxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitusCore Evid20105233721042540
   PubMedGoogle Scholar
• FrederichRMcNeillRBerglindNFlemingDChenRThe efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trialDiabetol Metab Syndr2012413622828124
   PubMed Web of Science ®Google Scholar
• DoucetJChacraAMaheuxPLuJHarrisSRosenstockJEfficacy and safety of saxagliptin in older patients with type 2 diabetes mellitusCurr Med Res Opin201127486386921323504
   PubMed Web of Science ®Google Scholar
• Onglyza® (saxagliptin) [prescribing information]PrincetonBristol-Myers Squibb Company2012
   Google Scholar
• BennettWLMaruthurNMSinghSComparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinationsAnn Intern Med2011154960261321403054
   PubMed Web of Science ®Google Scholar
• FilionKBJosephLBoivinJFSuissaSBrophyJMThiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitusPharmacoepidemiol Drug Saf201120878579621671441
   PubMed Web of Science ®Google Scholar
• LewisJDFerraraAPengTRisk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort studyDiabetes Care201134491692221447663
   PubMed Web of Science ®Google Scholar
• GallwitzBBenefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitusDrug Saf20103328710020082536
   PubMed Web of Science ®Google Scholar
• DruckerDJEnhancing incretin action for the treatment of type 2 diabetesDiabetes Care200326102929294014514604
   PubMed Web of Science ®Google Scholar
• DruckerDJThe biology of incretin hormonesCell Metab20063315316516517403
   PubMed Web of Science ®Google Scholar
• DruckerDJNauckMAThe incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesLancet200636895481696170517098089
   PubMed Web of Science ®Google Scholar
• RodbardHWJellingerPSDavidsonJAStatement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic controlEndocr Pract200915654055919858063
   PubMed Web of Science ®Google Scholar
• MillerMEBondsDEGersteinHCACCORD InvestigatorsThe effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD studyBMJ2010340b544420061360
   PubMed Web of Science ®Google Scholar
• ZoungasSChalmersJKengneAPThe efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trialDiabetes Res Clin Pract201089212613320541825
   PubMed Web of Science ®Google Scholar
• BondsDEMillerMEBergenstalRMThe association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD studyBMJ2010340b490920061358
   PubMed Web of Science ®Google Scholar
• CryerPEThe barrier of hypoglycemia in diabetesDiabetes200857123169317619033403
   PubMed Web of Science ®Google Scholar
• AhrénBFoleyJEFerranniniEChanges in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapyDiabetes Care201033473073220067974
   PubMed Web of Science ®Google Scholar
• PhungOJScholleJMTalwarMColemanCIEffect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetesJAMA2010303141410141820388897
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) GroupIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)Lancet199835291318378539742976
   PubMed Web of Science ®Google Scholar
• SchweizerADejagerSBosiEComparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trialDiabetes Obes Metab200911880481219476473
   PubMed Web of Science ®Google Scholar
• FerranniniEFonsecaVZinmanBFifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapyDiabetes Obes Metab200911215716619125777
   PubMed Web of Science ®Google Scholar
• Tradjenta™ (linagliptin) [prescribing information]RidgefieldBoehringer Ingelheim Pharmaceuticals, Inc.2011
   Google Scholar
• NowickiMRychlikIHallerHWarrenMLSuchowerLGause-NilssonID1680C00007 InvestigatorsSaxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairmentDiabetes Obes Metab201113652353221332627
   PubMed Web of Science ®Google Scholar